Sign In
Buy FULC
$3.22
+0.0800 (+2.55%)
At Close: Jun 03, 2026
CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically
Fulcrum Therapeutics™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Friday, 01'st Oct 2021
CAMBRIDGE, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically de
Fulcrum Therapeutics™ Announces Multiple Presentations During the Virtual Congress of the World Muscle Society
07:00am, Monday, 20'th Sep 2021
– Presentations highlight progress in the development of losmapimod for FSHD –
Fulcrum Therapeutics™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Friday, 10'th Sep 2021
CAMBRIDGE, Mass., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically d
Fulcrum Therapeutics: Multiple Interesting Programs, Needs A Better Entry Point
01:24am, Friday, 03'rd Sep 2021
Fulcrum Therapeutics: Multiple Interesting Programs, Needs A Better Entry Point
2 Soaring Biotech Stocks With More Fuel in the Tank
06:47am, Monday, 23'rd Aug 2021
These recent winners still have a long way to run.
Fulcrum Therapeutics Announces Pricing of $125 Million Public Offering of Common Stock
10:09pm, Wednesday, 11'th Aug 2021
CAMBRIDGE, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically de
Why Fulcrum Therapeutics Popped Again on Tuesday
04:06pm, Wednesday, 11'th Aug 2021
Compelling clinical-trial data that could validate the company's unique approach to new drug development inspired a slew of analyst upgrades.
Why Are Fulcrum Therapeutics Shares Trading Higher Today?
09:55am, Wednesday, 11'th Aug 2021
Fulcrum Therapeutics Inc (NASDAQ:FULC) is trading higher again Wednesday after the stock saw positive analyst coverage following the company's better-than-expected financial results and announcement
FULC Stock Price Increased 125.33%: Why It Happened
07:48am, Wednesday, 11'th Aug 2021
The stock price of Fulcrum Therapeutics Inc (NASDAQ: FULC) increased 125.33%. This is why it happened.
Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock
04:24pm, Tuesday, 10'th Aug 2021
CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically d
Why Fulcrum Therapeutics Shares Are Soaring Today
01:29pm, Tuesday, 10'th Aug 2021
Fulcrum Therapeutics Inc (NASDAQ: FULC) is surging higher Tuesday after the company reported results from its Phase 1 study of FTX-6058 for sickle cell disease showed proof of mechanism and proof of
Fulcrum Therapeutics, Inc. (FULC) CEO Bryan Stuart on Q2 2021 Results - Earnings Call Transcript
12:54pm, Tuesday, 10'th Aug 2021
Fulcrum Therapeutics, Inc. (FULC) CEO Bryan Stuart on Q2 2021 Results - Earnings Call Transcript
Here's Why Fulcrum Therapeutics Stock Is Shooting Higher Today
10:56am, Tuesday, 10'th Aug 2021
A positive trial readout suggests the company's new drug discovery engine has more potential than expected.
FULC Stock Price Increases Over 60% Pre-Market: Why It Happened
09:13am, Tuesday, 10'th Aug 2021
The stock price of Fulcrum Therapeutics Inc (NASDAQ: FULC) increased by over 60% pre-market. This is why it happened.
